• In May 2026, Tandem Diabetes Care filed a US$47.40 million shelf registration for 3,260,000 common shares linked to its employee stock ownership plan and separately secured CE mark approval in Europe to extend use of its t:slim X2 and Tandem Mobi automated insulin delivery systems to pregnancy in type 1 diabetes and adults with type 2 diabetes.
• This broader European certification opens access to new patient groups and care settings, potentially reinforcing Tandem’s role within integrated diabetes management solutions.
• Next, we’ll examine how this expanded CE mark indication, particularly into type 2 diabetes in Europe, may influence Tandem’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Tandem Diabetes Care Investment Narrative Recap

To own Tandem Diabetes Care, you need to believe its automated insulin delivery platforms can remain relevant as treatment standards shift and competition tightens. Near term, the key catalyst is execution on expanding pump adoption and renewals, while the biggest risk is that rival systems and evolving care models slow new starts. The new CE mark for pregnancy and type 2 in Europe may modestly support that adoption story, but does not remove competitive pressure.

The recent CE mark extension in Europe is closely tied to analysts’ more optimistic views on international expansion and direct sales. Broader use of t:slim X2 and Tandem Mobi across new European patient groups aligns with the idea that overseas markets can become a larger contributor to revenue and margins, especially as Tandem aims to capture more value per device and deepen its recurring consumables base outside the U.S.

Yet, while the expanded CE mark may support Tandem’s growth efforts, investors should still watch how intensifying competition could affect...

Tandem Diabetes Care's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029. This requires 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today.

Uncover how Tandem Diabetes Care's forecasts yield a $29.20 fair value, a 58% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts saw international expansion and pharmacy adoption lifting revenue to about US$1.6 billion and earnings to US$90.6 million, so it is worth asking whether the latest European approval brings the company closer to that view or exposes how far reality might differ from such bullish assumptions.

Explore 3 other fair value estimates on Tandem Diabetes Care - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.